JACC
HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
 QUICK SEARCH:   [advanced]


     


J Am Coll Cardiol, 2001; 37:398-406
© 2001 by the American College of Cardiology Foundation
This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Guazzi, M.
Right arrow Articles by Guazzi, M. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Guazzi, M.
Right arrow Articles by Guazzi, M. D.

CLINICAL STUDY: HEART FAILURE

Modulation of alveolar-capillary sodium handling as a mechanism of protection of gas transfer by enalapril, and not by losartan, in chronic heart failure

Marco Guazzi, MD, PhD, FACCa, Piergiuseppe Agostoni, MD, PhDa and Maurizio D. Guazzi, MD, PhDa

a Istituto di Cardiologia dell’Università degli Studi, Centro di Studio per le Ricerche Cardiovascolari del Consiglio Nazionale delle Ricerche, Centro Cardiologico, I.R.C.C.S., Milano, Italy

Manuscript received May 18, 2000; revised manuscript received August 18, 2000, accepted October 2, 2000.

Reprint requests and correspondence: Dr. Marco Guazzi, Istituto di Cardiologia, dell’Università degli Studi, Via C. Parea 4, 20138 Milan, Italy
marco.guazzi{at}cardiologicomonzino.it

OBJECTIVES

We sought to compare the protective efficacy of enalapril and losartan on lung diffusion in chronic heart failure (CHF).

BACKGROUND

In CHF, hydrostatic overload causes disruption of the alveolar-capillary membrane and depression of carbon monoxide diffusion (DCO); enalapril improves DCO through mechanisms still undefined; and saline infusion in the pulmonary circulation worsens DCO, putatively because of an upregulated sodium transport to the alveolar interstitium. We investigated whether enalapril modulates sodium handling and whether losartan shares the same properties.

METHODS

In 29 patients with CHF, DCO, its membrane diffusion subcomponent (DM) and right atrial and pulmonary wedge pressures were monitored during saline infusion, in the control condition, during enalapril therapy (20 mg/day) for two weeks and after crossover to losartan (50 mg/day) for two weeks (first 20 patients), or after the combination of enalapril with aspirin (325 mg/day) for one week (last 9 patients).

RESULTS

Saline, 150 ml, lowered DCO (–7.9%; p < 0.01) and DM (–9.9%; p < 0.01) without hydrostatic variations. Responses to 750 ml of saline were qualitatively similar. After treatment with enalapril, baseline DCO (p < 0.01) and DM (p < 0.01) were augmented; after sodium loading, the percent reductions of DCO (p < 0.01) and DM (p < 0.01) were comparable to those before it, resulting in higher absolute values. This suggests that the greater the gas conductance improvement with enalapril, the lower the impedance with saline. Losartan was ineffective on gas transfer at rest and under salt challenge. Aspirin counteracted the benefits of enalapril.

CONCLUSIONS

In CHF, enalapril protects lung diffusion, possibly through a prostaglandin-mediated modulation of sodium overfiltration to the alveolar interstitium; losartan does not share this ability.

Abbreviations and Acronyms
  ACE = angiotensin-converting enzyme
  AT1 = angiotensin type 1 receptor
  CHF = chronic heart failure
  DCO = diffusing capacity for carbon monoxide
  DM = alveolar-capillary membrane diffusing capacity
  HCT = hematocrit
  LVEF = left ventricular ejection fraction
  NE = norepinephrine
  PRA = plasma renin activity
  VA = alveolar volume
  Vc' = pulmonary capillary blood volume




This article has been cited by other articles:


Home page
Eur Heart JHome page
P. Agostoni, A. Magini, D. Andreini, M. Contini, A. Apostolo, M. Bussotti, G. Cattadori, and P. Palermo
Spironolactone improves lung diffusion in chronic heart failure
Eur. Heart J., January 2, 2005; 26(2): 159 - 164.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
M. Guazzi, G. Tumminello, F. Di Marco, C. Fiorentini, and M. D. Guazzi
The effects of phosphodiesterase-5 inhibition with sildenafil on pulmonary hemodynamics and diffusion capacity, exercise ventilatory efficiency, and oxygen uptake kinetics in chronic heart failure
J. Am. Coll. Cardiol., December 21, 2004; 44(12): 2339 - 2348.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
M. Guazzi, G. Tumminello, M. Matturri, and M. D. Guazzi
Insulin ameliorates exercise ventilatory efficiency and oxygen uptake in patients with heart failure-type 2 diabetes comorbidity
J. Am. Coll. Cardiol., September 17, 2003; 42(6): 1044 - 1050.
[Abstract] [Full Text] [PDF]


Home page
ChestHome page
M. Guazzi
Alveolar-Capillary Membrane Dysfunction in Heart Failure: Evidence of a Pathophysiologic Role
Chest, September 1, 2003; 124(3): 1090 - 1102.
[Abstract] [Full Text] [PDF]


Home page
Arch Intern MedHome page
M. Guazzi, R. Brambilla, G. Reina, G. Tumminello, and M. D. Guazzi
Aspirin-Angiotensin-Converting Enzyme Inhibitor Coadministration and Mortality in Patients With Heart Failure: A Dose-Related Adverse Effect of Aspirin
Arch Intern Med, July 14, 2003; 163(13): 1574 - 1579.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
M Guazzi, G Pontone, R Brambilla, P Agostoni, and G Reina
Alveolar-capillary membrane gas conductance: a novel prognostic indicator in chronic heart failure
Eur. Heart J., March 2, 2002; 23(6): 467 - 476.
[Abstract] [Full Text] [PDF]




HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
Copyright © 2001 by the American College of Cardiology Foundation.